Tafluprost - Generic Drug Details

What are the generic sources for tafluprost and what is the scope of patent protection?

Tafluprost is the generic ingredient in two branded drugs marketed by Ingenus Pharms Llc, Micro Labs, Sandoz, and Thea Pharma, and is included in four NDAs. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Tafluprost has eighty-five patent family members in twenty-six countries.

There are three drug master file entries for tafluprost. Five suppliers are listed for this compound.

Summary for tafluprost

International Patents:	85
US Patents:	2
Tradenames:	2
Applicants:	4
NDAs:	4
Drug Master File Entries:	3
Finished Product Suppliers / Packagers:	5
Raw Ingredient (Bulk) Api Vendors:	62
Clinical Trials:	29
Patent Applications:	1,958
Drug Prices:	Drug price trends for tafluprost
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for tafluprost
What excipients (inactive ingredients) are in tafluprost?	tafluprost excipients list
DailyMed Link:	tafluprost at DailyMed

See drug prices for tafluprost

Recent Clinical Trials for tafluprost

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Fondazione G.B. Bietti, IRCCS	Phase 4
Tun Hussein Onn National Eye Hospital	Phase 4
Taejoon Pharmaceutical Co., Ltd.	Phase 4

See all tafluprost clinical trials

Pharmacology for tafluprost

Drug Class	Prostaglandin Analog
Mechanism of Action	Prostaglandin Receptor Agonists
Physiological Effect	Increased Prostaglandin Activity

Anatomical Therapeutic Chemical (ATC) Classes for tafluprost

S01EE	Prostaglandin analogues
S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

Paragraph IV (Patent) Challenges for TAFLUPROST

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ZIOPTAN	Ophthalmic Solution	tafluprost	0.0015%	202514	2	2016-02-10

US Patents and Regulatory Information for tafluprost

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ingenus Pharms Llc	TAFLUPROST	tafluprost	SOLUTION/DROPS;OPHTHALMIC	218002-001	Apr 5, 2024	AT	RX	No	No
Thea Pharma	ZIOPTAN	tafluprost	SOLUTION/DROPS;OPHTHALMIC	202514-001	Feb 10, 2012	AT	RX	Yes	Yes			Y
Thea Pharma	ZIOPTAN	tafluprost	SOLUTION/DROPS;OPHTHALMIC	202514-001	Feb 10, 2012	AT	RX	Yes	Yes			Y
Micro Labs	TAFLUPROST	tafluprost	SOLUTION/DROPS;OPHTHALMIC	209051-001	Aug 19, 2019	AT	RX	No	No
Sandoz	TAFLUPROST	tafluprost	SOLUTION/DROPS;OPHTHALMIC	209040-001	Jan 28, 2022	AT	RX	No	No

Expired US Patents for tafluprost

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Thea Pharma	ZIOPTAN	tafluprost	SOLUTION/DROPS;OPHTHALMIC	202514-001	Feb 10, 2012

International Patents for tafluprost

Country	Patent Number	Title	Estimated Expiration
Georgia, Republic of	P20156220
Japan	2016065095	高眼圧症及び緑内障を治療するための方法及び組成物 (METHOD AND COMPOSITION FOR TREATING OCULAR HYPERTENSION AND GLAUCOMA)
Eurasian Patent Organization	201071413
Argentina	071937	METODO Y COMPOSICION PARA TRATAR HIPERTENSION OCULAR Y GLAUCOMA QUE COMPRENDE ANALOGOS DE PGF-2ALFA, USO Y METODO PARA AUMENTAR LA SOLUBILIDAD ACUOSA Y MEJORAR LA ESTABILIDAD DE LOS ANALOGOS DE PGF-2ALFA
Japan	2018154656
Taiwan	201000104	Method and composition for treating ocular hypertension and glaucoma

Supplementary Protection Certificates for tafluprost

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0850926	SPC/GB09/005	United Kingdom		PRODUCT NAME: TAFLUPROST OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: DK 43230 20080430; UK PL 16058/0011-0001 20081017
0850926	11C0020	France		PRODUCT NAME: TAFLUPROST; REGISTRATION NO/DATE IN FRANCE: CIS:6 000 728 O DU 20110328; REGISTRATION NO/DATE AT EEC: 43230 DU 20080430
0850926	C00850926/01	Switzerland		PRODUCT NAME: TAFLUPROST; REGISTRATION NO/DATE: SWISSMEDIC 60548 27.01.2010

Market Dynamics and Financial Trajectory for Tafluprost

Last updated: February 20, 2026

What is Tafluprost and How Does It Fit in the Ophthalmology Market?

Tafluprost is a prostaglandin analog used primarily to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. It gained approval from the U.S. Food and Drug Administration (FDA) in 2012 under the brand name Zioptan. The drug functions by increasing uveoscleral outflow, reducing the risk of optic nerve damage caused by elevated IOP. Its unique preservative-free formulation aims to reduce ocular irritation risks associated with preservatives like benzalkonium chloride.

Market Size and Forecast

Global Glaucoma Treatment Market

The global market for glaucoma medications was valued at approximately $5.8 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 4.5% from 2023 to 2030, reaching roughly $8.4 billion by 2030 [1].

Tafluprost’s Market Position

Tafluprost's share within this market remains modest at around 4% of the total glaucoma drug market, owing to competition from established drugs such as latanoprost, bimatoprost, and travoprost. Its revenue in 2022 is estimated near $230 million globally, with sales concentrated in North America and Europe.

Sales Trajectory

The sales forecast for Tafluprost indicates annual growth of approximately 7-9% over the next five years, driven by:

• Increasing diagnosis rates of glaucoma (approx. 60 million annual cases worldwide)
• Rising adoption of preservative-free formulations
• Expanding approval for use in additional indications, such as ocular hypertension with scarce existing treatments

Competitive Dynamics

Key Competitors

Drug	Market Share (2022)	Formulation Type	Unique Selling Point	Approvals
Latanoprost	55%	Preservative-based	Established efficacy, affordability	Multiple generics available
Bimatoprost	20%	Preservative-based	Enhanced ocular penetration	Widely prescribed
Travoprost	12%	Preservative-based	Longer duration of action	Approved in multiple countries
Tafluprost	4%	Preservative-free	Reduced ocular irritation, preservative-free	Most approvals in North America, Europe

Key Differentiators

Tafluprost’s preservative-free formulation is increasingly attractive to patients sensitive to ocular preservatives. It targets a niche of patients with ocular surface disease or those intolerant to other prostaglandins.

Regulatory Landscape

In 2020, the FDA approved generic Tafluprost, which could pressure branded sales, although the preservative-free aspect remains a differentiation point. European regulators have approved Tafluprost since 2011, supporting its regional growth.

Financial Impact Drivers

Revenue Opportunities

• Expansion into emerging markets with rising glaucoma prevalence
• Introduction of combination therapies incorporating Tafluprost
• Lifecycle management through new delivery systems, such as sustained-release devices

Cost Factors

• Manufacturing costs for preservative-free formulations remain higher due to specialized packaging
• R&D expenditures for new indications or formulations
• Marketing investments to increase awareness among ophthalmologists and optometrists

Risks

• Patent expiry for Zioptan in key markets (not scheduled until 2027 in the U.S.)
• Pricing pressures from generics
• Competition from novel drug classes, including Rho kinase inhibitors

Market Entry and Growth Strategies

• Collaborations with regional distributors to penetrate Asia-Pacific, which accounts for approximately 25% of global glaucoma cases
• Clinical trials assessing Tafluprost’s efficacy in combination therapies
• Developing patient-friendly delivery methods to expand patient adherence and satisfaction

Conclusion

Tafluprost’s market dynamics reflect its positioning as a niche product with growing acceptance due to its preservative-free formulation. Its financial trajectory depends on market expansion, competitive pressures, and regulatory developments. While current sales figures are modest compared to market leaders, sustained growth is feasible with strategic marketing, geographic expansion, and pipeline innovation.

---

Key Takeaways

• Tafluprost held a 4% share of the global glaucoma treatment market in 2022 with estimated revenues of $230 million.
• Market growth is driven by rising glaucoma prevalence, with forecasts suggesting a 7-9% annual increase for Tafluprost sales over the next five years.
• Competitive advantages include its preservative-free formulation, but generic competition and patent expiry are risks.
• Expansion into emerging markets and development of combination therapies are core to growth strategies.
• Regulatory approvals and regional distribution partnerships are pivotal for market penetration.

---

FAQs

1. How does Tafluprost differ from other prostaglandin analogs?
Tafluprost is preservative-free, reducing ocular surface irritation and suitable for sensitive patients. It has similar efficacy but offers a better tolerability profile.

2. What is the impact of patent expiry on Tafluprost sales?
Patent expiry in the U.S. is scheduled for 2027, after which generic versions are likely to lower prices and reduce branded sales margins.

3. Which regions present the highest growth potential for Tafluprost?
Asia-Pacific and Latin America are emerging markets with increasing glaucoma prevalence and growing healthcare infrastructure, representing high growth potential.

4. Are there any new formulations or delivery systems under development?
Research includes sustained-release implants and injectable formulations aimed at improving adherence and reducing dosing frequency.

5. What are the main barriers to market expansion for Tafluprost?
Price competition from generics, limited brand recognition outside North America and Europe, and regulatory hurdles in some countries hinder rapid expansion.

---

References

[1] MarketsandMarkets. (2023). Global Glaucoma Drugs Market. https://www.marketsandmarkets.com